Article History
Received: 14 December 2022
Accepted: 4 April 2023
First Online: 21 April 2023
Declarations
:
: The study protocol was approved by the Institutional Review Board at the University of Maryland, Baltimore, USA. CHB patients and healthy donors provided written informed consent to participate in this study.
: All authors consent for publication.
: SK received grants from Gilead, Arbutus and Merck, and advises for Merck. The others have no competing interest to declare.